✦ LIBER ✦

879 PRECLINICAL STUDY OF NEW NANOPARTICLES WITH ANTICANCER AND MRI FUNCTIONS

✍ Scribed by J.W. Lee; J.I. Lee; D.H. Lee; Y.S. Kim; S.-S. Hong; J.-H. Maeng; K.-H. Jung

Book ID: 117378960
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 69 KB
Volume: 52
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(10)60880-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Progress in preclinical and clinical stu

Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes

✍ N. Saijo; Kazuto Nishio; S. Ohta; Hitoshi Arioka; Yasunori Funayama; Kazuya Fuku 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 108 KB

Increased rates of atrophy in early and

Increased rates of atrophy in early and preclinical AD: Studies with registration of serial MRI

✍ Nicholas C. Fox 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 181 KB

Preclinical toxicity studies of kahalali

Preclinical toxicity studies of kahalalide F, a new anticancer agent: single and multiple dosing regimens in the rat

✍ Alan P. Brown; Robert L. Morrissey; Glynn T. Faircloth; Barry S. Levine 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 108 KB

KP1019, A New Redox-Active Anticancer Ag

KP1019, A New Redox-Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients

✍ Christian G. Hartinger; Michael A. Jakupec; Stefanie Zorbas-Seifried; Michael Gr 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB 👁 1 views

## Abstract The promising drug candidate indazolium __trans__‐[tetrachlorobis(1__H__‐indazole)ruthenate(III)] (KP1019) is the second Ru‐based anticancer agent to enter clinical trials. In this review, which is an update of a paper from 2006 (__Hartinger et al., J. Inorg. Biochem.__ **2006**, __100_

A Density Functional Study of a New Fami

A Density Functional Study of a New Family of Anticancer Drugs: Paclitaxel, Taxotere, Epothilone, and Discodermolide

✍ Ballone, P.; Marchi, M. 📂 Article 📅 1999 🏛 American Chemical Society 🌐 English ⚖ 114 KB

ChemInform Abstract: KP1019, A New Redox

ChemInform Abstract: KP1019, A New Redox-Active Anticancer Agent — Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients

✍ Christian G. Hartinger; Michael A. Jakupec; Stefanie Zorbas-Seifried; Michael Gr 📂 Article 📅 2009 🏛 John Wiley and Sons ⚖ 16 KB 👁 1 views

## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable v